Celldex Therapeutics Inc.

23.55-0.0100-0.04%Vol 307.47K1Y Perf 1 139.15%
Apr 16th, 2021 16:00 DELAYED
BID23.56 ASK23.61
Open24.09 Previous Close23.56
Pre-Market- After-Market23.49
 - -  -0.06 -0.25%
Target Price
34.33 
Analyst Rating
Strong Buy 1.00
Potential %
45.77 
Finscreener Ranking
★★★★+     57.50
Insiders Trans % 3/6/12 mo.
-/-100/56 
Value Ranking
★★★★     57.74
Insiders Value % 3/6/12 mo.
-/-100/-49 
Growth Ranking
★★★     53.19
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/34 
Income Ranking
 —    -
Market Cap932.93M 
Earnings Rating
Buy
Price Range Ratio 52W %
76.61 
Earnings Date
5th May 2021

Today's Price Range

22.9424.17

52W Range

1.8730.17

5 Year PE Ratio Range

-2.20-0.8000

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
13.71%
1 Month
-5.65%
3 Months
34.34%
6 Months
49.43%
1 Year
1 139.15%
3 Years
98.73%
5 Years
-66.16%
10 Years
-61.23%

TickerPriceChg.Chg.%
CLDX23.55-0.0100-0.04
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
13.80
13.90
0.01
0.02
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-668.30
-615.30
-1 330.70
-
RevenueValueIndustryS&P 500US Markets
4.69M
0.12
-27.02
-3.91
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.37-0.2629.73
Q03 2020-0.34-0.36-5.88
Q02 2020-0.77-0.5725.97
Q01 2020-0.70-0.73-4.29
Q04 2019--0.64-
Q03 2019-0.84-0.7510.71
Q02 2019-1.17-0.8428.21
Q01 2019-1.14-1.130.88
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.3278.08Positive
6/2021 QR-0.3479.88Positive
12/2021 FY-1.41--
12/2022 FY-1.43--
Next Report Date5th May 2021
Estimated EPS Next Report-0.32
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume307.47K
Shares Outstanding39.62M
Trades Count4.60K
Dollar Volume20.38M
Avg. Volume695.67K
Avg. Weekly Volume336.85K
Avg. Monthly Volume958.50K
Avg. Quarterly Volume721.75K

Celldex Therapeutics Inc. (NASDAQ: CLDX) stock closed at 23.55 per share at the end of the most recent trading day (a -0.04% change compared to the prior day closing price) with a volume of 310.42K shares and market capitalization of 932.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 130 people. Celldex Therapeutics Inc. CEO is Anthony S. Marucci.

The one-year performance of Celldex Therapeutics Inc. stock is 1139.15%, while year-to-date (YTD) performance is 34.42%. CLDX stock has a five-year performance of -66.16%. Its 52-week range is between 1.87 and 30.17, which gives CLDX stock a 52-week price range ratio of 76.61%

Celldex Therapeutics Inc. currently has a PE ratio of -9.70, a price-to-book (PB) ratio of 3.97, a price-to-sale (PS) ratio of 175.60, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.34%, a ROC of -28.52% and a ROE of -38.35%. The company’s profit margin is -%, its EBITDA margin is -615.30%, and its revenue ttm is $4.69 Million , which makes it $0.12 revenue per share.

Of the last four earnings reports from Celldex Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. Celldex Therapeutics Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Celldex Therapeutics Inc. is Strong Buy (1), with a target price of $34.33, which is +45.77% compared to the current price. The earnings rating for Celldex Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Celldex Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Celldex Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.36, ATR14 : 1.96, CCI20 : 37.59, Chaikin Money Flow : 0.14, MACD : -0.05, Money Flow Index : 26.15, ROC : 19.36, RSI : 67.03, STOCH (14,3) : 90.09, STOCH RSI : 0.99, UO : 59.23, Williams %R : -9.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Celldex Therapeutics Inc. in the last 12-months were: Anthony S. Marucci (Buy at a value of $45 900), Diane C. Young (Buy at a value of $10 004), James J. Marino (Buy at a value of $24 915), Margo Heath-Chiozzi (Buy at a value of $3 005), Richard M. Wright (Option Excercise at a value of $129 365), Richard M. Wright (Sold 20 832 shares of value $387 611 ), Sam Martin (Buy at a value of $29 738), Sarah Cavanaugh (Buy at a value of $5 072), Tibor Keler (Buy at a value of $14 954)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Celldex Therapeutics Inc.

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.

CEO: Anthony S. Marucci

Telephone: +1 908 200-7500

Address: 53 Frontage Road, Hampton 08827, NJ, US

Number of employees: 130

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

61%39%

Bearish Bullish

50%50%

News

Stocktwits